Telix Pharmaceuticals Ltd (ASX: TLX) shares are on the slide on Monday morning.

At the time of writing, the ASX healthcare stock is down 2.5% to $11.03.

Why are Telix Pharmaceuticals shares falling today?

Investors have been selling the company’s shares today after it announced the resubmission of a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for its brain cancer imaging candidate TLX101-Px, also known as Pixclara.

According to the release, the NDA relates to an investigational PET imaging agent designed to help characterise recurrent or progressive glioma, a form of brain cancer, in both adult and paediatric patients.

Telix advised that the application has been resubmitted with additional data requested by the FDA. The company believes the new data and statistical analysis, together with the original submission, address the issues raised in the regulator’s earlier Complete Response Letter.

The imaging candidate has already received both Orphan Drug and Fast Track designations from the FDA, reflecting its potential to address a significant unmet medical need.

Importantly, management highlights that while PET imaging with the tracer is already included in international clinical guidelines for imaging gliomas, there is currently no FDA-approved targeted amino acid PET imaging agent commercially available in the United States for brain cancer imaging.

Potential companion diagnostic

Telix also noted that TLX101-Px may serve as a companion diagnostic for its therapeutic candidate TLX101-Tx, which is being investigated as a treatment for glioblastoma in the IPAX-BrIGHT study.

Gliomas are among the most common types of brain tumours, accounting for around 30% of all brain and central nervous system tumours and approximately 80% of malignant brain tumours.

Commenting on the resubmission, Telix’s chief medical officer, Dr David N. Cade, said:

We appreciate the FDA’s recognition of the critical unmet need to improve the diagnosis and management of glioma, particularly in the posttreatment setting. Our resubmission is supported by an extensive and compelling data set – particularly so for an orphan indication. We are grateful to our global clinical collaborators, who share our commitment to ensuring patients in the U.S. can benefit from this important patient management tool.

Also commenting on the news was Maggie Haynes, who is executive director at Head for the Cure Foundation. Hayne added:

Our community is encouraged by the FDA’s ongoing engagement and guidance to the sponsor and support for the Expanded Access Program for TLX101-Px. We are hopeful of an expedited review, so this important and proven imaging option can become available to those who urgently need it.

The post Telix shares drop despite promising US FDA update appeared first on The Motley Fool Australia.

More reading

• Telix Pharmaceuticals resubmits FDA application for brain cancer imaging agent
• These are the 10 most shorted ASX shares
• Here are the top 10 ASX 200 shares today
• Why Telix shares could smash the market in 2026 with an 80% return
• Should you buy low on these ASX healthcare stocks?

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

In uncertain times like this, there are particular ASX-listed exchange-traded funds (ETFs) that could provide strong returns over the long-term which I’m drawn to.

The short-term may be volatile, but that can happen every so often on the share market. Sometimes the world can throw up a big unexpected event which cause share prices to drop.

Earnings of some businesses may well fall. But, some may fare better than others because of the quality metrics they possess.

I want to highlight two funds in-particular that have performed strongly over the long-term and could be resilient through whatever happens next. But, I have a positive view about the long-term.

Betashares Global Quality Leaders ETF (ASX: QLTY)

This ETF represents a global portfolio of 150 companies that are ranked by the highest quality score.

By owning 150 businesses from across the world and in different sectors, it offers investors significant diversification, much more than what the S&P/ASX 200 Index (ASX: XJO) currently provides.

BetaShares says that the quality score rankings used to select the stocks in the index are based on a combined ranking of four key factors – return on equity (ROE), debt-to-capital, cash flow generation ability and earnings stability.

In other words, these businesses make a lot of profit for shareholders, they use little-to-no debt to do so, they generate plenty of cash flow and their earnings are stable. But combining these elements, I think you’re left with many of the world highest-quality companies in the portfolio.

Over the three years to the end of February 2026, the QLTY ETF returned an average of 17.3% per year, which is an excellent return, in my view. Past performance is not a guarantee of future returns of course.

I’m backing the ASX ETF’s portfolio to continue delivering good results over time.

VanEck MSCI International Quality ETF (ASX: QUAL)

The QUAL ETF has a somewhat similar setup – it’s aiming to provide investors with a high-quality global portfolio that is decided by a few quality-based metrics.

It doesn’t look at quite as many quality characteristics, but it does own twice as many shares as the QLTY ETF. In terms of the number of different names it provides exposure to, it does have more diversification.

The three metrics that this ASX ETF looks for is a high return on equity, earnings stability and low financial leverage. In other words, these businesses are very profitable on behalf of shareholders’ funds, the profit is resilient and doesn’t usually go backwards, and these companies don’t utilise much, if any debt, as part of the business.

Impressively, to 28 February 2026, it has returned an average of 20.3% per year over the prior three years, though that’s not a guarantee of future returns.

The post 2 ASX ETFs I’d buy for returns and to sleep well at night appeared first on The Motley Fool Australia.

More reading

• 3 defensive ASX ETFs to battle through market turmoil
• This would be my $1 million ASX retirement portfolio
• 3 of the best ASX ETFs to buy and hold forever
• The easy way to invest globally is with these ASX ETFs
• 5 fantastic ASX ETFs to buy and hold for 10 years

Motley Fool contributor Tristan Harrison has positions in VanEck Msci International Quality ETF. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Perpetual Ltd (ASX: PPT) share price is in focus after the company announced the sale of its Wealth Management business to Bain Capital for an upfront $500 million, plus potential further payments.

What did Perpetual report?

• Binding deal to sell Wealth Management division to Bain Capital for $500 million cash up front
• Potential additional upfront payment, dependent on advice business performance to completion (up to $50 million)
• Earn-out component of up to $50 million, tied to Wealth business performance post-completion
• Net proceeds will be used to reduce company debt and invest in Asset Management and Corporate Trust businesses
• Pro-forma net debt to EBITDA expected to fall to around 0.2x after completion

What else do investors need to know?

Completion of the transaction is subject to approvals from the Foreign Investment Review Board (FIRB), the ACCC, and a corporate restructure to separate Wealth Management from the Perpetual Group. Completion is targeted towards the end of 2026.

Transaction and separation costs are expected to be around $30 million (post-tax) over the next 12–18 months. Estimated tax on proceeds is $45–50 million, with franking credits from this available for future dividends, likely from 2H27.

Perpetual will license its Wealth-related brands to Bain Capital for 15 years but will retain full ownership of the core “Perpetual” brand. Transitional support services for technology and operations will be provided to the Wealth Management business for up to 18 months post-completion.

What did Perpetual management say?

Perpetual CEO and Managing Director Bernard Reilly said:

Following a thorough sale process, we believe we have achieved the right outcome for our shareholders, clients and people, and one that reflects Wealth Management’s longstanding reputation as a premium provider of high net worth advisory, fiduciary, philanthropic and not-for-profit offerings in the Australian market.

This is a pivotal step in our strategy to simplify and transform Perpetual. Following completion, Perpetual will have a stronger balance sheet and more simplified business, focused on two core businesses, asset management and corporate trustee services, while also enhancing its ability to invest for future growth and deliver improved shareholder returns over the longer term.

We believe we have found the right owner for the Wealth Management business to help it continue to grow and deliver high quality products and services to its clients. Today’s announcement also provides clarity and certainty for our teams, who have continued to show an exceptionally high level of professionalism, commitment and focus throughout this process.

What’s next for Perpetual?

With the Wealth Management sale, Perpetual will concentrate on its core Asset Management and Corporate Trust operations. The business expects to use sale proceeds to pay down debt and fund further growth in these divisions.

Over the coming months, the group will progress the required regulatory and court approvals for completion, and provide transitional support to the Wealth Management business until it is fully separated. The simplification aims to position Perpetual for long-term growth and improved shareholder returns.

Perpetual share price snapshot

Over the past 12 months, Perpetual shares declined 12%, trailing the S&P/ASX 200 Index (ASX: XJO) which has risen 10% over the same period.

View Original Announcement

The post Perpetual sells Wealth Management business to Bain Capital for $500m appeared first on The Motley Fool Australia.

More reading

• Orica settles US litigation and announces US acquisition
• Lynas Rare Earths announces US$96m US rare earth agreement
• Telix Pharmaceuticals resubmits FDA application for brain cancer imaging agent
• Meridian Energy: February 2026 update shows growth and strong storage
• 5 things to watch on the ASX 200 on Monday

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

Northern Star Resources Ltd (ASX: NST) shares have been struggling in recent months.

Due to production issues, the ASX 200 gold giant is down 32% from its 52-week high to $21.75.

While this is disappointing for shareholders, Bell Potter thinks it could be a buying opportunity for the rest of us.

What is the broker saying about this ASX 200 gold giant?

Bell Potter was very disappointed to see the company downgrade its FY 2026 guidance for a second time last week. It said:

NST have downgraded FY26 guidance for a second time this FY, just when we thought NST were seeing light at the end of the tunnel. Gold sales are now expected to be at or around 1,500koz down from the previously revised 1,600-1,700koz guidance (BPe 1,601koz, VA 1,614koz prior to the downgrade).

The reasons driving the downgrade primarily stemmed from KCGM mill throughput challenges with intermittent outages in the float circuit and electrical issues compounding downtime. Throughput over the remainder of the year is likely to average ~9Mtpa vs the initial 12Mtpa FY26 guidance. Adding insult to injury, productivity at Jundee continued to disappoint with grades failing to meet expectations and prompting a shift in resources to higher-margin operations.

While the ASX 200 gold stock has reaffirmed its cost guidance for FY 2026, Bell Potter believes that this will be removed with its third-quarter result. The broker explains:

Management reaffirmed AISC guidance of A$2,600- $2,800/oz, however on our assessment this is likely to be pulled potentially at the 3Q result. Total group gold sales across Jan-Feb were 220koz (2QFY26 348koz), we have pared back our estimate for KCGM, adjusting throughput to 7.4Mtpa (annualized) in 3Q and 10.4Mtpa in 4Q at an average grade of 1.8g/t. We remain sceptical on the throughput grade required to meet the updated guidance, given mined grades are tracking around 1.6g/t and being delivered for processing through the new Mill in FY27.

Should you buy Northern Star shares?

Despite the many negatives, Bell Potter remains positive on the ASX 200 gold giant and believes it could be a good time to buy.

It has retained its buy rating and $35.00 price target, which implies potential upside of 60% for investors over the next 12 months.

Commenting on its recommendation, the broker said:

Our Target Price is unchanged at $35.00/sh, and we maintain our Buy recommendation. The disappointing downgrade however is likely to remain as a significant overhang for the stock over the next 12-18m until the ramp up of the upgraded mill at KCGM commences. We see potential positives from asset rationalisation, given the high capital and operating costs at the likes of Jundee and Thunderbox.

The post What Bell Potter is saying about this fallen ASX 200 gold giant appeared first on The Motley Fool Australia.

More reading

• Northern Star Resources shares just crashed – time to buy the dip?
• 5 things to watch on the ASX 200 on Monday
• Why CAR Group, Immutep, Northern Star, and Syrah Resources shares are sinking today
• Northern Star shares crash 16% on second guidance downgrade for FY26
• Northern Star trims FY26 guidance and updates on KCGM mill expansion

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Orica Ltd (ASX: ORI) share price is in focus today after the company announced the settlement of US litigation and a new acquisition in North America. Highlights include resolving the CF Industries dispute for US$169.5 million and moving to acquire Nelson Brothers’ US explosives business.

What did Orica report?

• Settled litigation with CF Industries for US$169.5 million, funded from existing cash and undrawn debt facilities
• Agreement to acquire Nelson Brothers’ US explosives business for US$25 million plus retirement of US$48 million in debt
• Transactions expected to be earnings per share (EPS) accretive in the first full financial year
• Acquisition to boost EBIT by AUD$35 million per year once fully integrated
• Increased exposure to the strategic North American market, especially US Quarries and Construction sectors

What else do investors need to know?

Orica’s settlement with CF Industries brings an end to litigation that began in October 2023, with no admission of liability by either party. This move removes a significant source of uncertainty for Orica’s shareholders and customers.

The acquisition of Nelson Brothers’ explosives business will give Orica full ownership of four US emulsion plants and wider access to downstream markets. The deal also expands Orica’s exposure in critical end markets through improved supply chain and delivery capabilities, plus enhanced opportunities for cross-selling its product and service offerings.

What did Orica management say?

Orica Managing Director and CEO Sanjeev Gandhi said:

Orica has agreed to settle this litigation with CF following careful consideration and in the best interests of shareholders and customers. Our focus remains on executing our strategy, advancing our growth initiatives and delivering sustainable value for customers and shareholders.

Importantly, our actions have ensured there has been no disruption to customer supply, and we remain committed to strengthening security of supply for our customers through a diversified and resilient sourcing strategy in North America.

The combination of the settlement and the acquisition of Nelson Brothers’ US Explosives business will further strengthen our North American region, deliver immediate earnings benefits and support our strategy to grow in attractive downstream markets.

What’s next for Orica?

Looking ahead, Orica expects the combination of the litigation settlement and new acquisition to simplify its business structure and create greater operational resilience. Management sees upside through increased presence in the attractive North American market, as well as potential revenue growth and business synergies from the Nelson Brothers acquisition.

The integration of the newly acquired business and a move to diversify Orica’s ammonium nitrate supply are aimed at supporting sustainable long-term growth and further protecting customer supply chains.

Orica share price snapshot

Over the past 12 months, Orica shares have risen 11%, slightly outperforming the S&P/ASX 200 Index (ASX: XJO) which has risen 10% over the same period.

View Original Announcement

The post Orica settles US litigation and announces US acquisition appeared first on The Motley Fool Australia.

More reading

• Lynas Rare Earths announces US$96m US rare earth agreement
• Telix Pharmaceuticals resubmits FDA application for brain cancer imaging agent
• Meridian Energy: February 2026 update shows growth and strong storage
• 5 things to watch on the ASX 200 on Monday
• Here’s why ASX 200 energy shares were the only risers last week

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

Reliance Worldwide Ltd (ASX: RWC) has announced a new $120 million share buyback, after its gearing levels fell below their target range.

The company said in a statement to the ASX that the new buyback was in addition to a US$15.3 million buyback announced on February 17, which was part of its interim distribution which also included a US2 cents per share dividend.

Company performing well

Reliance chair Russell Chenu said the buyback reflected the board’s confidence in the company’s strategy and outlook.

He said further:

RWC has continued to generate strong cash flows over the past two years despite subdued end markets. This has enabled us to substantially reduce net debt. Consequently, RWC’s leverage ratio has fallen below the bottom end of our target range of 1.5 time to 2.5 times net debt to EBITDA1. Undertaking this additional share buy-back will enable us to return excess capital to shareholders efficiently and is consistent with our previously articulated capital management strategy. We expect to be comfortably within the leverage ratio target range at the conclusion of the $120 million buy-back.

Reliance in mid-February said it had had a challenging first half, with its results impacted by US tariffs and weaker demand in the US and the UK.

Sales revenue was 4% lower at US$645.4 million for the first half while net profit was 34.9% lower at US$43.7 million.

The company added:

As foreshadowed in RWC’s FY25 earnings announcement in August 2025, operating earnings for the period were adversely impacted by US tariffs. The expected full year net impact of tariffs in FY26 is in the range of US$25 million to US$30 million, with the impact weighted to the first half of FY26. The benefits from the transfer of product sourcing away from China to lower tariff countries, coupled with price adjustments and cost reduction measures, will continue to flow through in the second half of FY26.

Reliance chief executive officer Heath Sharp said the first half had been “particularly challenging” due to the US tariffs and weak markets.

He added:

While residential remodelling and new construction markets remained subdued, we have made significant progress on a number of strategic initiatives. We commissioned our new assembly facility in Poland and finalised plans for a new facility in Mexico which will support activity in the Americas and lower the impact of associated tariffs. During the half we also launched new product ranges with key distributors in Germany, France and Italy, while SharkBite Max was launched nationwide across Australia.

Morgans in February released a research note to its clients on Reliance and has a price target of $3.50 on Reliance Worldwide shares, compared with $2.92 currently.

Reliance Worldwide was valued at $2.24 billion at the close of trade on Friday.

The post Which industrial company has just announced a $120 million buyback? appeared first on The Motley Fool Australia.

More reading

• 3 ASX 200 shares at 52-week lows: Buy, hold, or sell?
• 35 ASX All Ords shares with ex-dividend dates next week
• After being sold down on weak results, one broker thinks Reliance Worldwide is a good buy
• Why Reliance, Santana Minerals, Sims, and Treasury Wine shares are falling today
• Reliance Worldwide half-year earnings: profit falls, dividend steady

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Several ASX shares are under pressure following the latest S&P Dow Jones Indices rebalance.

Catapult Sports Ltd (ASX: CAT), EBOS Group Ltd (ASX: EBO), and DigiCo Infrastructure REIT (ASX: DGT) slid between roughly 4.3% and 11% after it was announced they will be removed from the S&P/ASX 200 Index (ASX: XJO) later this month.

Index removals can trigger selling pressure as exchange-traded funds and index funds that track the benchmark are forced to offload the stocks. While the move doesn’t change the underlying businesses, it can still create short-term volatility.

Here’s a closer look at the 3 affected ASX shares.

Catapult Sports: struggle to deliver consistent profits

This ASX share has lost 51% of its value over 6 months to just $1 billion. Catapult develops performance analytics technology used by professional sports teams around the world. Its wearable tracking devices and video analysis software are widely used across leagues such as the NFL, NBA, and English Premier League.

Catapult operates in a niche but rapidly growing market. As professional sports become increasingly data-driven, demand for performance analytics continues to expand.

The company also benefits from a recurring software revenue model. Subscription income from teams using its analytics platforms helps provide more predictable revenue compared with traditional hardware businesses.

Despite its growth potential, Catapult has historically struggled to consistently deliver strong profits. Investors remain sensitive to execution risk as the company balances growth investments with improving margins.

Another risk is its relatively small size compared with many ASX 200 companies. Smaller technology firms can experience larger share price swings, particularly when sentiment toward growth stocks weakens.

Ebos Group: defensive business, thin margins

Ebos Group is one of the largest healthcare and pharmaceutical distributors across Australia and New Zealand. The ASX share also owns a growing portfolio of animal care and healthcare brands.

Ebos operates in a defensive sector. Demand for pharmaceuticals, medical supplies, and healthcare services tends to remain relatively stable regardless of broader economic conditions.

The company has also grown significantly through acquisitions, building a diversified healthcare distribution network and expanding its product portfolio across both human and animal health markets.

Strong cash flow generation has helped support consistent dividends, making the stock popular with income-focused investors.

Despite its defensive positioning, Ebos operates on relatively thin margins typical of the distribution sector. Rising costs or pricing pressure from suppliers could impact profitability.

The $3.8 billion ASX share has tumbled 31% in the past 6 months and 22% so far in 2026.

DigiCo Infrastructure REIT: focus on data centre capacity

DigiCo Infrastructure REIT is a relatively new ASX share and focuses on digital infrastructure assets. It particularly targets data centres that support cloud computing and growing data demand.

Digital infrastructure has become a critical part of the global economy. Rapid growth in cloud services, artificial intelligence, and data storage is driving strong long-term demand for data centre capacity.

As a newer listing, DigiCo has a shorter track record compared with many established ASX infrastructure companies. That can make it harder for investors to assess long-term performance.

Since being listed in December 2024 the ASX share has dropped steadily with 64% to $1.81. DigiCo’s market capitalisation has been reduced to just $1 billion.

Foolish Takeaway

Being removed from the S&P/ASX 200 Index can create short-term selling pressure, but it doesn’t necessarily change a company’s long-term prospects.

For investors willing to look beyond the index reshuffle, Catapult Sports, Ebos Group, and DigiCo Infrastructure REIT may still be worth watching closely.

The post 3 ASX shares slide after being cut from the ASX 200 appeared first on The Motley Fool Australia.

More reading

• Top brokers name 3 ASX shares to buy next week
• What’s going on with this ASX tech share?
• Why Catapult Sports, CBA, Dyno Nobel, and Qantas shares are sinking today
• Leading brokers name 3 ASX shares to buy today
• Bell Potter names more of the best ASX shares to buy in March

Motley Fool contributor Marc Van Dinther has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Catapult Sports. The Motley Fool Australia has positions in and has recommended Catapult Sports. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Lynas Rare Earths Ltd (ASX: LYC) share price is in focus today after the company announced a major supply agreement with the US Department of War, involving US$96 million in rare earth oxide offtake and a US$110/kg floor price for NdPr.

What did Lynas Rare Earths report?

• Signed a binding Letter of Intent with the United States Department of War (DoW) for rare earth supply.
• US$96 million allocated by the US Government for Light and Heavy Rare Earth oxide purchases from Lynas.
• NdPr oxide floor price set at US$110 per kilogram under the supply framework.
• The proposed agreement covers deliveries over a four-year period.
• This follows changes to an earlier agreement regarding the Seadrift, Texas facility.

What else do investors need to know?

Lynas’ agreement with the US Department of War establishes a framework to finalise a longer-term supply arrangement. This move is designed to support US national security and strengthen supply chain resilience around essential rare earth materials.

The revised arrangement comes after mutual decisions to modify the original deal, reflecting uncertainty about progressing the Heavy Rare Earth processing facility at Seadrift, Texas. Lynas and the DoW are also in discussion about future supply needs for Heavy Rare Earth oxides.

What did Lynas Rare Earths management say?

CEO and Managing Director Amanda Lacaze said:

Lynas is pleased to sign this binding Letter of Intent with the U.S. Department of War. Through this agreement, the U.S. Defense Industrial Base will continue to have access to Light and Heavy Rare Earth oxides that are essential for modern manufacturing.

We thank the U.S. Government for working with Lynas to reach this mutually beneficial arrangement and look forward to finalising the definitive agreement in due course and continuing our productive engagement with the U.S. Government.

What’s next for Lynas Rare Earths?

Looking ahead, Lynas and the DoW will work towards converting this Letter of Intent into a definitive long-term agreement. Further talks are underway for extended supply, including potentially expanding the scope for Heavy Rare Earth oxides.

Lynas continues to be a key player in global rare earth supply, and its focus remains on serving strategic customers while supporting critical industry needs, particularly in the US.

Lynas Rare Earths share price snapshot

Over the past 12 months, Lynas Rare Earths shares have risen 172%, outperforming the S&P/ASX 200 Index (ASX: XJO) which has risen 10% over the same period.

View Original Announcement

The post Lynas Rare Earths announces US$96m US rare earth agreement appeared first on The Motley Fool Australia.

More reading

• Orica settles US litigation and announces US acquisition
• Telix Pharmaceuticals resubmits FDA application for brain cancer imaging agent
• Meridian Energy: February 2026 update shows growth and strong storage
• These are the 10 most shorted ASX shares
• 5 things to watch on the ASX 200 on Monday

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Lynas Rare Earths Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

The Telix Pharmaceuticals Ltd (ASX: TLX) share price is in focus after the company announced it has resubmitted its New Drug Application (NDA) to the U.S. FDA for TLX101-Px (Pixclara®), a brain cancer imaging candidate. Telix’s resubmission includes new data addressing the FDA’s previous requests and could bring the first FDA-approved targeted PET agent for adult and paediatric brain cancer imaging to the U.S. market.

What did Telix Pharmaceuticals report?

• Resubmitted NDA for TLX101-Px (Pixclara®) brain cancer imaging agent to U.S. FDA
• Submission includes additional data and statistical analysis to address FDA’s Complete Response Letter
• TLX101-Px has Orphan Drug and Fast Track designations from the FDA
• No FDA‑approved targeted amino acid PET agent currently available for brain cancer imaging in the U.S.
• TLX101-Px is intended for both adult and paediatric glioma imaging

What else do investors need to know?

TLX101-Px is being developed to help doctors distinguish between recurrent or progressing glioma and changes caused by prior treatments. This could make a real difference for patients struggling with brain cancer by helping their clinical teams make better informed decisions.

Globally, PET imaging with 18F-FET (the basis for TLX101-Px) is part of clinical guidelines, but no similar FDA-approved product exists in the U.S. The agent targets LAT1 and LAT2 transport proteins and also has potential as a companion diagnostic for Telix’s investigational brain cancer therapy, TLX101-Tx.

Telix has operations spanning the U.S., Europe, Japan, and other countries, and is headquartered here in Melbourne. Its Illuccix® imaging agent is already approved in multiple markets. However, both TLX101-Px and the therapy TLX101-Tx are investigational and not yet approved anywhere.

What did Telix Pharmaceuticals management say?

Dr. David N. Cade, Telix Group Chief Medical Officer, said:

We appreciate the FDA’s recognition of the critical unmet need to improve the diagnosis and management of glioma, particularly in the post-treatment setting. Our resubmission is supported by an extensive and compelling data set – particularly so for an orphan indication. We are grateful to our global clinical collaborators, who share our commitment to ensuring patients in the U.S. can benefit from this important patient management tool.

What’s next for Telix Pharmaceuticals?

Telix expects the FDA review process to progress in the coming months after its resubmission. With Orphan Drug and Fast Track status, the company could potentially see an expedited pathway to approval, if the regulator is satisfied with the new data.

In the meantime, Telix continues work on its broader pipeline, including further development of both imaging and therapeutic products for cancer and rare diseases worldwide. Investors will be watching for updates on FDA timelines and any developments in the pivotal study of TLX101-Tx.

Telix Pharmaceuticals share price snapshot

Over the past 12 months, Telix shares have declined 59%, trailing the S&P/ASX 200 Index (ASX: XJO) which has risen 10% over the same period.

View Original Announcement

The post Telix Pharmaceuticals resubmits FDA application for brain cancer imaging agent appeared first on The Motley Fool Australia.

More reading

• Orica settles US litigation and announces US acquisition
• Lynas Rare Earths announces US$96m US rare earth agreement
• Meridian Energy: February 2026 update shows growth and strong storage
• These are the 10 most shorted ASX shares
• 5 things to watch on the ASX 200 on Monday

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

Oil prices have surged again as the war in the Middle East continues to disrupt global energy supply.

According to Trading Economics, West Texas Intermediate (WTI) crude rose 1.06% to US$99.75 per barrel, while Brent crude is trading above US$103 per barrel. Prices have rallied sharply since the conflict began in late February.

The rise in oil has also pushed broader commodity markets higher, lifting products linked to diversified commodity indices such as the Global X Bloomberg Commodity Complex ETF (ASX: BCOM).

War in the Middle East hits global oil flows

The latest rally follows a significant disruption to global energy supply caused by the ongoing war involving Iran, the United States, and Israel.

The Strait of Hormuz, a narrow shipping lane between Iran and Oman, normally carries around 20 million barrels of oil per day, representing roughly 20% of global oil trade.

Since the conflict escalated, tanker traffic through the strait has collapsed and maritime shipments have slowed dramatically.

The International Energy Agency (IEA) estimates that oil production across Gulf states including Saudi Arabia, Iraq, Kuwait, and the United Arab Emirates has already been reduced by at least 10 million barrels per day. This makes it the largest supply disruption in the history of the oil market.

Oil prices briefly surged as high as US$119 per barrel earlier this month, the highest level since 2022, before easing slightly.

Several oil export facilities have also been affected by military strikes and attacks on infrastructure. In one incident, a fire at the Fujairah oil hub in the United Arab Emirates forced loading operations to stop at a port that previously exported around 1.7 million barrels per day.

Commodity markets move higher alongside oil

The rise in oil prices has contributed to gains across the broader commodity complex.

One investment reflecting this move is the Global X Bloomberg Commodity Complex ETF.

The BCOM share price closed at $13.22 on 13 March, up 1.38% for the day. Over the past month the ETF has risen 10.44%, while its 1-year return is 14.96%.

The ETF tracks the Bloomberg Commodity Index, which includes exposure to a diversified group of commodities across multiple sectors.

These include energy products, precious metals, industrial metals, agricultural commodities, grains, and livestock.

This broad exposure distinguishes it from many commodity ETFs that track a single market such as gold, oil, or agriculture.

Oil markets remain sensitive to developments

Oil markets remain highly sensitive to developments in the Middle East war.

The IEA has already coordinated the release of around 400 million barrels of oil from strategic reserves in an effort to stabilise global markets.

However, analysts warn that strategic reserves can only offset supply losses for a limited period if shipping through the Strait of Hormuz remains restricted.

With oil now trading close to US$100 per barrel, the conflict has become a major driver of commodity prices and global energy markets.

The post Oil climbs toward US$100 as the Middle East war disrupts global supply appeared first on The Motley Fool Australia.

More reading

• What Bell Potter is saying about this fallen ASX 200 gold giant
• Orica settles US litigation and announces US acquisition
• Which industrial company has just announced a $120 million buyback?
• 3 ASX shares slide after being cut from the ASX 200
• Lynas Rare Earths announces US$96m US rare earth agreement

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.